The draft updated guidance on assessing and preventing falls in older people and people aged 50 and over at higher risk opens ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...

Belzutifan (Welireg, Merck Sharp & Dohme) is indicated for 'the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), ...

Belzutifan (Welireg) is available during the managed access period. It is a possible treatment for tumours associated with von Hippel-Lindau (VHL) disease in adults when localised procedures such as ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Next review: More evidence on belzutifan is being collected. After this, NICE will decide whether to recommend it for use in the NHS and update the guidance. It will be available to patients as part ...

when localised procedures are unsuitable or undesirable. It is only recommended if the conditions in the managed access agreement for belzutifan are followed. This recommendation is not intended to ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Demand for NHS Talking Therapies has reached an all-time high. The service received 1.82 million referrals in 2023/24. This is slightly higher than 2021/2022, and more than double the 884,000 received ...